Clinical & Translational Immunology (Jan 2023)

Plasma SARS‐CoV‐2 RNA elimination and RAGE kinetics distinguish COVID‐19 severity

  • Xiaoyan Deng,
  • Pierre Gantner,
  • Julia Forestell,
  • Amélie Pagliuzza,
  • Elsa Brunet‐Ratnasingham,
  • Madeleine Durand,
  • Daniel E Kaufmann,
  • Nicolas Chomont,
  • Morgan Craig

DOI
https://doi.org/10.1002/cti2.1468
Journal volume & issue
Vol. 12, no. 11
pp. n/a – n/a

Abstract

Read online

Abstract Objectives Identifying biomarkers causing differential SARS‐CoV‐2 infection kinetics associated with severe COVID‐19 is fundamental for effective diagnostics and therapeutic planning. Methods In this work, we applied mathematical modelling to investigate the relationships between patient characteristics, plasma SARS‐CoV‐2 RNA dynamics and COVID‐19 severity. Using a straightforward mathematical model of within‐host viral kinetics, we estimated key model parameters from serial plasma viral RNA (vRNA) samples from 256 hospitalised COVID‐19+ patients. Results Our model predicted that clearance rates distinguish key differences in plasma vRNA kinetics and severe COVID‐19. Moreover, our analyses revealed a strong correlation between plasma vRNA kinetics and plasma receptor for advanced glycation end products (RAGE) concentrations (a plasma biomarker of lung damage), collected in parallel to plasma vRNA from patients in our cohort, suggesting that RAGE can substitute for viral plasma shedding dynamics to prospectively classify seriously ill patients. Conclusion Overall, our study identifies factors of COVID‐19 severity, supports interventions to accelerate viral clearance and underlines the importance of mathematical modelling to better understand COVID‐19.

Keywords